Robin Peter

UC Berkeley

“Small-scale dosimetry and tumor control of 225Ac radiopharmaceuticals in a preclinical prostate cancer mouse model”

Due to the short alpha-particle range and often heterogeneous distribution of targeting agents, cancer treatment using alpha-emitting radiopharmaceuticals can be subject to dose heterogeneity within target and non-target tissues. Without micro-scale characterization, high-uptake dose-limiting regions within nonuniform organs at risk can go unidentified. To help identify vulnerable sub-organ regions in humans, this work studies the microscopic distribution of 225Ac-radiopharmaceutical alpha-particle dose in murine models of prostate cancer (PCa) using microscale ex vivo dosimetry. Using image processing, 2D digital autoradiographs are combined into 3D anatomical models used to evaluate tumor control probability and dose to sub-organ structures.


Alpha-particle therapy is a promising alternative treatment for metastatic cancers that requires improved dose characterization and imaging to be clinically safe and relevant. This work demonstrates the first 3D digital autoradiography measurements for alpha-particle therapy in a mouse model using [225Ac]Ac-Macropa-PEG4-YS5, a novel alpha-particle radiopharmaceutical for prostate cancer.

5 + 5 =